J&J Golimumab BLA Filing Planned For First Half 2008 In Three Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson’s Centocor unit is positioning the next generation anti-TNF as a once-monthly treatment.
You may also be interested in...
Centocor Hits A Triple With Golimumab
Three Phase III trials prove TNF blocker works in RA – even after others in the class failed.
Centocor Hits A Triple With Golimumab
Three Phase III trials prove TNF blocker works in RA – even after others in the class failed.
J&J Combines Ortho Biotech, Centocor
At least 400 jobs lost to fallout from anemia-drug troubles.